Get the Stockscreener App
21.32
0.85%
-0.20
Xencor Inc stock is traded at $21.32, with a volume of 83,827.
It is down -0.85% in the last 24 hours and up +7.49% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
See More
Previous Close:
$21.52
Open:
$21.31
24h Volume:
83,827
Relative Volume:
0.18
Market Cap:
$1.50B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-9.9626
EPS:
-2.14
Net Cash Flow:
$23.50M
1W Performance:
-1.08%
1M Performance:
+7.49%
6M Performance:
-11.50%
1Y Performance:
+15.65%
1-Day Range:
$21.01
$21.65
1-Week Range:
$20.84
$22.00
52-Week Range:
$15.31
$26.84
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Trading (XNCR) With Integrated Risk Controls - Stock Traders Daily
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - BioSpace
Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? - Yahoo Finance
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts - Defense World
How to Take Advantage of moves in (XNCR) - Stock Traders Daily
Essex LLC Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Creative Planning Sells 3,356 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
State Street Corp's Strategic Reduction in Xencor Inc Holdings - GuruFocus.com
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know - Yahoo Finance
(XNCR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
AQR Capital Management LLC Invests $753,000 in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy - Simply Wall St
Xencor to begin human trials for bowel disease antibody - Investing.com
Xencor to begin human trials for bowel disease antibody By Investing.com - Investing.com Canada
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire
Blastic Plasmacytoid Dendritic Cell Neoplasm Market By The 2031 | Cellex Patient Treatment GmbH, AbbVie Inc, Xencor, Genentech, Inc, ImmunoGen, Inc – Times-BD24 - Times-BD24
Xencor board member to depart, company seeks new talent - Investing.com
Xencor board member to depart, company seeks new talent By Investing.com - Investing.com South Africa
Xencor Board Member Dagmar Rosa-Bjorkeson to Step Down - TipRanks
Xencor Announces Upcoming Change to Board of Directors - StockTitan
How To Trade (XNCR) - Stock Traders Daily
Xencor’s $175 Million Common Stock Underwritten Public Offering - Global Legal Chronicle
Point72 Asia Singapore Pte. Ltd. Buys New Shares in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Dimensional Fund Advisors LP Has $27.63 Million Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Dimensional Fund Advisors LP Purchases 87,979 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Analytical Overview: Xencor Inc (XNCR)’s Ratios Tell a Financial Story - The Dwinnex
Monitoring Xencor Inc (XNCR) after recent insider movements - Knox Daily
Xencor executive sells over $54k in company stock - Investing.com India
Xencor director Richard Ranieri sells over $50k in company stock - Investing.com India
Xencor executive sells over $54k in company stock By Investing.com - Investing.com Australia
Xencor executive sells over $50k in company stock - Investing.com India
Xencor executive Dagmar Rosa-Bjorkeson sells shares worth over $51k - Investing.com
Xencor executive sells over $50k in company stock By Investing.com - Investing.com Canada
Cubist Systematic Strategies LLC Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Position Boosted by American Century Companies Inc. - Defense World
Xencor's SWOT analysis: biotech stock's potential in protein engineering - Investing.com
XTX Topco Ltd Acquires New Shares in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Point72 Asset Management L.P. Increases Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Short Interest in Xencor, Inc. (NASDAQ:XNCR) Increases By 24.8% - MarketBeat
Point72 Asia Singapore Pte. Ltd. Acquires New Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Point72 Asset Management L.P. Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RANIERI RICHARD J | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
8,490 |
| GUSTAFSON KURT A | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
9,490 |
| GORMAN KEVIN CHARLES | Director |
Sep 27 '24 |
Sale |
20.68 |
2,654 |
54,885 |
8,392 |
| Montgomery Alan Bruce | Director |
Sep 27 '24 |
Sale |
20.68 |
1,853 |
38,320 |
9,140 |
| Feigal Ellen | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
8,490 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):